Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Verkerk

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Frontiers in Pharmacology|March 7, 2022
Tracking TRYCAT: A Critical Appraisal of Kynurenine Pathway Quantifications in BloodViolette Coppens, Robert Verkerk, Manuel Morrens
Journal of Molecular Neuroscience : MN|October 2, 2015
Serum Phenylalanine, Tyrosine, and their Ratio in Acute Ischemic Stroke: on the Trail of a Biomarker?Heidi Ormstad, Robert Verkerk, Leiv Sandvik
Neuro Endocrinology Letters|June 30, 2011
Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activityMichael Maes, Piotr Galecki, Robert Verkerk, et al.
Analytical Biochemistry|April 2, 2005
Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrateJohan Willemse, Judith Leurs, Robert Verkerk, et al.
Journal of Molecular Neuroscience : MN|March 26, 2014
Activation of the kynurenine pathway in the acute phase of stroke and its role in fatigue and depression following strokeHeidi Ormstad, Robert Verkerk, Karl-Friedrich Amthor, et al.
Life Sciences|March 1, 2005
Serotonergic disturbances in autistic disorder: L-5-hydroxytryptophan administration to autistic youngsters increases the blood concentrations of serotonin in patients but not in controlsJan Croonenberghs, Robert Verkerk, Simon Scharpe, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 31, 2016
Increased plasma levels of competing amino acids, rather than lowered plasma tryptophan levels, are associated with a non-response to treatment in major depressionHeidi Ormstad, Johan Dahl, Robert Verkerk, et al.
Neuro Endocrinology Letters|August 19, 2007
Central serotonergic hypofunction in autism: results of the 5-hydroxy-tryptophan challenge testJan Croonenberghs, Annick Wauters, Dirk Deboutte, et al.
Life Sciences|August 15, 2002
Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activationMichael Maes, Robert Verkerk, Stephania Bonaccorso, et al.
Neuropsychobiology|January 20, 2004
Psychobiological aspects of somatoform disorders: contributions of monoaminergic transmitter systemsWinfried Rief, Florian Pilger, Daniel Ihle, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Frontiers in Pharmacology|March 7, 2022
Tracking TRYCAT: A Critical Appraisal of Kynurenine Pathway Quantifications in BloodViolette Coppens, Robert Verkerk, Manuel Morrens
Journal of Molecular Neuroscience : MN|October 2, 2015
Serum Phenylalanine, Tyrosine, and their Ratio in Acute Ischemic Stroke: on the Trail of a Biomarker?Heidi Ormstad, Robert Verkerk, Leiv Sandvik
Neuro Endocrinology Letters|June 30, 2011
Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activityMichael Maes, Piotr Galecki, Robert Verkerk, et al.
Analytical Biochemistry|April 2, 2005
Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrateJohan Willemse, Judith Leurs, Robert Verkerk, et al.
Journal of Molecular Neuroscience : MN|March 26, 2014
Activation of the kynurenine pathway in the acute phase of stroke and its role in fatigue and depression following strokeHeidi Ormstad, Robert Verkerk, Karl-Friedrich Amthor, et al.
Life Sciences|March 1, 2005
Serotonergic disturbances in autistic disorder: L-5-hydroxytryptophan administration to autistic youngsters increases the blood concentrations of serotonin in patients but not in controlsJan Croonenberghs, Robert Verkerk, Simon Scharpe, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 31, 2016
Increased plasma levels of competing amino acids, rather than lowered plasma tryptophan levels, are associated with a non-response to treatment in major depressionHeidi Ormstad, Johan Dahl, Robert Verkerk, et al.
Neuro Endocrinology Letters|August 19, 2007
Central serotonergic hypofunction in autism: results of the 5-hydroxy-tryptophan challenge testJan Croonenberghs, Annick Wauters, Dirk Deboutte, et al.
Life Sciences|August 15, 2002
Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activationMichael Maes, Robert Verkerk, Stephania Bonaccorso, et al.
Neuropsychobiology|January 20, 2004
Psychobiological aspects of somatoform disorders: contributions of monoaminergic transmitter systemsWinfried Rief, Florian Pilger, Daniel Ihle, et al.
Pageof 4